The CoopERA BC study compared the efficacy and safety of neoadjuvant giredestrant versus anastrozole plus palbociclib in the treatment of ER‐positive, HER2‐negative, postmenopausal early breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.